Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Kymera Therapeutics (KYMR) over the last 1 years, with Dec 2024 value amounting to $1.9 million.

  • Kymera Therapeutics' Gains from Investment Securities was N/A to $1.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.7 million, marking a year-over-year change of. This contributed to the annual value of -$168,000 for FY2024, which is 100.34% down from last year.
  • As of Q4 2024, Kymera Therapeutics' Gains from Investment Securities stood at $1.9 million, which was up 203.12% from -$1.9 million recorded in Q3 2024.
  • Kymera Therapeutics' Gains from Investment Securities' 5-year high stood at $48.8 million during Q1 2023, with a 5-year trough of -$1.9 million in Q3 2024.
  • Over the past 3 years, Kymera Therapeutics' median Gains from Investment Securities value was $998,000 (recorded in 2022), while the average stood at $9.9 million.
  • Data for Kymera Therapeutics' Gains from Investment Securities shows a maximum YoY crashed of 50.35% (in 2022) over the last 5 years.
  • Over the past 4 years, Kymera Therapeutics' Gains from Investment Securities (Quarterly) stood at $2.0 million in 2021, then crashed by 50.35% to $998,000 in 2022, then reached $48.8 million in 2023, then reached $1.9 million in 2024.
  • Its Gains from Investment Securities stands at $1.9 million for Q4 2024, versus -$1.9 million for Q3 2024 and -$227,000 for Q2 2024.